Orphan Drugs Service Market Research Explores Growth Within A $93.93 Billion Opportunity

The orphan drugs service market has become a crucial area of focus in recent years, driven by advances in medical research and regulatory changes. As the understanding of rare diseases deepens, the demand for specialized treatments and support services continues to rise. Let's explore the market's current size, what's fueling its growth, key players, noteworthy trends, and how the market is segmented for a comprehensive understanding.

Projected Expansion of the Orphan Drugs Service Market by 2030
The orphan drugs service market has experienced swift growth recently, with its value anticipated to climb from $43.4 billion in 2025 to $50.75 billion in 2026. This represents a compound annual growth rate (CAGR) of 16.9%. Factors contributing to this increase in the past include improved identification of rare diseases, expanded orphan drug legislation, rising investment in rare disease research, availability of regulatory incentives, and the growing influence of patient advocacy organizations.

Download a free sample of the orphan drugs service market report:
https://thebusinessresearchcompany.com/sample_request?id=96333236&type=smp&name=Orphan%20Drugs%20Service%20Market%20Report%202026&utm_source=OpenPR&utm_medium=Paid&utm_campaign=Oct_PR

Looking ahead, the market is expected to continue its rapid upward trajectory, reaching $93.93 billion by 2030 with a CAGR of 16.6%. The forecasted growth is driven by rising demand for personalized therapies targeting rare diseases, the adoption of cutting-edge clinical trial technologies, broadening global orphan drug pipelines, increased use of real-world evidence, and ongoing regulatory support for orphan drug development. Key trends shaping this growth include heightened demand for specialized regulatory and development services, emphasis on accelerated approval pathways, greater use of data-driven platforms for rare disease research, patient-centric clinical development models, and strengthened collaboration among stakeholders.

Top Companies Steering the Orphan Drugs Service Market
Several prominent corporations are leading the orphan drugs service market, including Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd., Pfizer Inc., AbbVie Inc., Bayer AG, Sanofi S.A., Novartis AG, AstraZeneca PLC, The Bristol-Myers Squibb Company, GSK plc., Eli Lilly and Company, Takeda Pharmaceutical Company Limited, Amgen Inc., IQVIA Inc., CSL Behring GmbH, Lonza Group AG, BioMarin Pharmaceutical Inc., Fortrea Holdings Inc., Medpace Inc., Sarepta Therapeutics, Caidya Inc., and Cevidra Inc.

View the full orphan drugs service market report:
https://www.thebusinessresearchcompany.com/report/orphan-drugs-service-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Oct_PR

In a notable recent development, Norgine B.V., a pharmaceutical company based in the Netherlands, acquired Theravia Pharma in April 2025 for an undisclosed sum. This acquisition aims to strengthen Norgine's growth strategy and expand its portfolio of rare disease therapies, particularly in Europe and the Australia-New Zealand region (ANZ). Theravia Pharma, headquartered in France, specializes in rare diseases and orphan drug services, enhancing Norgine's position as a key player in the rare and specialty pharmaceuticals sector.

Noteworthy Trends Shaping the Orphan Drugs Service Market
A major focus for leading companies in the orphan drugs service market is securing regulatory approvals to speed up the development and availability of treatments for rare diseases. Such approvals, granted by government bodies, permit new drugs or therapies to be legally tested, manufactured, and marketed to patients.

For example, in February 2023, U.S.-based gene therapy company Askbio GmbH received orphan drug designation from the European Commission for AB-1003, an investigational gene therapy targeting limb-girdle muscular dystrophy. This therapy, based on an adeno-associated virus (AAV) vector, is designed to restore FKRP enzyme activity in muscle cells through a one-time intravenous infusion. AB-1003 has also earned orphan drug designations from both the European Commission and the U.S. Food and Drug Administration (FDA), along with rare pediatric disease and fast track designations from the FDA. It is currently undergoing a Phase 1/2 clinical trial (LION-CS101) to evaluate safety and effectiveness in adults with genetically confirmed limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9).

Details on Market Segments Covered in the Orphan Drugs Service Report
The orphan drugs service market is categorized in the report according to several dimensions:

1) By Type: Congenital Disease, Genetic Disease, Tumors and Cancer, Chronic, Other Types
2) By Therapeutic Area: Oncology, Metabolic Disorders, Neurological Disorders, Hematology, Infectious Diseases, Other Rare Diseases
3) By Application: Adult, Children

Further subsegments include classifications such as:
- Congenital Disease: Heart Defects, Cleft Lip and Palate, Spina Bifida, Down Syndrome
- Genetic Disease: Cystic Fibrosis, Huntington Disease, Sickle Cell Anemia, Muscular Dystrophy
- Tumors and Cancer: Leukemia, Lymphoma, Neuroblastoma, Sarcoma
- Chronic: Rare Metabolic Disorders, Rare Endocrine Disorders, Rare Cardiovascular Disorders, Rare Neurological Disorders
- Other Types: Rare Infectious Diseases, Rare Immunological Disorders, Rare Dermatological Conditions, Rare Ophthalmological Disorders

This detailed segmentation allows for an in-depth understanding of the orphan drugs service market's diverse and specialized areas.

New strategic additions in our 2026 market reports include market attractiveness scoring and analysis, total addressable market (TAM) analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technologies and future trend analysis, along with updated graphics and tables.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 30,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.